Modulation of the Renin-Angiotensin-aldosterone system in heart failure

J. George; A. D. Struthers; C. C. Lang

doi:10.1007/s11883-014-0403-7

Modulation of the Renin-Angiotensin-aldosterone system in heart failure

J. George, A. D. Struthers, C. C. Lang (Lead / Corresponding author)

Molecular and Clinical Medicine

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

The renin-angiotensin-aldosterone system (RAAS) is well-established and continues to be pursued as a therapeutic target in the treatment of heart failure, predominantly due to the success of agents that block RAAS in clinical trials of systolic heart failure. The optimal treatment of heart failure patients with preserved ejection fraction (HFpEF), however, remains unclear. Early trials of direct renin inhibitors have suggested that these agents may play a role in HFpEF, but recent clinical trial results have not been encouraging. Preliminary trials of angiotensin-receptor/neprilysin inhibitors look promising. Whether results with these or other drugs will alter current recommendations remains to be seen. In this review, we assess the current understanding of the role of RAAS modulation in heart failure.

Original language	English
Pages (from-to)	403
Number of pages	1
Journal	Current Atherosclerosis Reports
Volume	16
Issue number	4
DOIs	https://doi.org/10.1007/s11883-014-0403-7
Publication status	Published - Apr 2014

Access to Document

10.1007/s11883-014-0403-7

Cite this

@article{6e1bd91bd6e24ea2926130ccab9a02fc,

title = "Modulation of the Renin-Angiotensin-aldosterone system in heart failure",

abstract = "The renin-angiotensin-aldosterone system (RAAS) is well-established and continues to be pursued as a therapeutic target in the treatment of heart failure, predominantly due to the success of agents that block RAAS in clinical trials of systolic heart failure. The optimal treatment of heart failure patients with preserved ejection fraction (HFpEF), however, remains unclear. Early trials of direct renin inhibitors have suggested that these agents may play a role in HFpEF, but recent clinical trial results have not been encouraging. Preliminary trials of angiotensin-receptor/neprilysin inhibitors look promising. Whether results with these or other drugs will alter current recommendations remains to be seen. In this review, we assess the current understanding of the role of RAAS modulation in heart failure.",

author = "J. George and Struthers, {A. D.} and Lang, {C. C.}",

year = "2014",

month = apr,

doi = "10.1007/s11883-014-0403-7",

language = "English",

volume = "16",

pages = "403",

journal = "Current Atherosclerosis Reports",

issn = "1523-3804",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Modulation of the Renin-Angiotensin-aldosterone system in heart failure

AU - George, J.

AU - Struthers, A. D.

AU - Lang, C. C.

PY - 2014/4

Y1 - 2014/4

N2 - The renin-angiotensin-aldosterone system (RAAS) is well-established and continues to be pursued as a therapeutic target in the treatment of heart failure, predominantly due to the success of agents that block RAAS in clinical trials of systolic heart failure. The optimal treatment of heart failure patients with preserved ejection fraction (HFpEF), however, remains unclear. Early trials of direct renin inhibitors have suggested that these agents may play a role in HFpEF, but recent clinical trial results have not been encouraging. Preliminary trials of angiotensin-receptor/neprilysin inhibitors look promising. Whether results with these or other drugs will alter current recommendations remains to be seen. In this review, we assess the current understanding of the role of RAAS modulation in heart failure.

AB - The renin-angiotensin-aldosterone system (RAAS) is well-established and continues to be pursued as a therapeutic target in the treatment of heart failure, predominantly due to the success of agents that block RAAS in clinical trials of systolic heart failure. The optimal treatment of heart failure patients with preserved ejection fraction (HFpEF), however, remains unclear. Early trials of direct renin inhibitors have suggested that these agents may play a role in HFpEF, but recent clinical trial results have not been encouraging. Preliminary trials of angiotensin-receptor/neprilysin inhibitors look promising. Whether results with these or other drugs will alter current recommendations remains to be seen. In this review, we assess the current understanding of the role of RAAS modulation in heart failure.

U2 - 10.1007/s11883-014-0403-7

DO - 10.1007/s11883-014-0403-7

M3 - Article

C2 - 24510580

SN - 1523-3804

VL - 16

SP - 403

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

IS - 4

ER -

Modulation of the Renin-Angiotensin-aldosterone system in heart failure

Abstract

Access to Document

Fingerprint

Cite this